J. Lipid Res. Please sign the JLR Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baker, P. W.
Right arrow Articles by Barter, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, P. W.
Right arrow Articles by Barter, P. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Journal of Lipid Research, Vol. 40, 345-353, February 1999
Copyright © 1999 by Lipid Research, Inc.


Original Article

Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells

Paul W. Bakera,b, Kerry-Anne Ryeb,c, Jennifer R. Gambleb, Mathew A. Vadasb, and Philip J. Bartera,b,c
a University Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia
b Hanson Centre, Institute of Medical and Veterinary Science, Adelaide, Australia
c Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, Australia

Correspondence to: Paul W. Baker

Previous studies have shown that both high density lipoproteins (HDL) isolated from human plasma and reconstituted HDL (rHDL) are effective inhibitors of adhesion molecule expression in human endothelial cells. In this study rHDL have been used to investigate whether HDL particle shape, size, apolipoprotein composition or lipid composition are important determinants of the ability of HDL to inhibit the TNF-{alpha} induced expression of vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). On the basis of these studies it is possible to draw several firm conclusions. i) Neither phospholipid-containing vesicles nor lipid-free apolipoprotein (apo) A-I inhibit VCAM-1 expression in HUVECs. ii) Simple discoidal complexes containing only phospholipid and apoA-I (discoidal (A-I)rHDL) are sufficient to inhibit the TNF-{alpha}-induced expression of VCAM-1 in HUVECs. iii) Spherical apoA-I-containing rHDL (spherical (A-I)rHDL) are superior to discoidal (A-I)rHDL as inhibitors. iv) The particle size of spherical (A-I)rHDL has no influence on the inhibition. v) Spherical rHDL that contain apoA-I are superior as inhibitors of VCAM-1 to those containing apoA-II when the rHDL preparations are equated for apolipoprotein molarity. However, when compared at equivalent particle molarities, this difference is no longer apparent. vi) Replacement of cholesteryl esters with triglyceride in the core of spherical (A-I)rHDL has no effect on the ability of these particles to inhibit VCAM-1 expression.

From these results it is tempting to speculate that variations in inhibitory activity may contribute to the variations observed in the anti-atherogenicity of different HDL subpopulations.—Baker, P. W., K-A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 1999. 40: 345–353.

Supplementary key words: reconstituted HDL, endothelial cells, VCAM-1, phospholipids, apolipoproteins


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
E. M. deGoma, R. L. deGoma, and D. J. Rader
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.
J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Mastorikou, M. Mackness, and B. Mackness
Defective Metabolism of Oxidized Phospholipid by HDL From People With Type 2 Diabetes
Diabetes, November 1, 2006; 55(11): 3099 - 3103.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. J. Nicholls, P. Lundman, J. A. Harmer, B. Cutri, K. A. Griffiths, K.-A. Rye, P. J. Barter, and D. S. Celermajer
Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 715 - 720.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Kee, D. Caiazza, K.-A. Rye, P.H.R. Barrett, L.A. Morehouse, and P.J. Barter
Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits
Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 884 - 890.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. J. Nicholls, B. Cutri, S. G. Worthley, P. Kee, K.-A. Rye, S. Bao, and P. J. Barter
Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits
Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2416 - 2421.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. J. Nicholls, G. J. Dusting, B. Cutri, S. Bao, G. R. Drummond, K.-A. Rye, and P. J. Barter
Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits
Circulation, March 29, 2005; 111(12): 1543 - 1550.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman
Antiinflammatory Properties of HDL
Circ. Res., October 15, 2004; 95(8): 764 - 772.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
E. Boisfer, D. Stengel, D. Pastier, P. M. Laplaud, N. Dousset, E. Ninio, and A.-D. Kalopissis
Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II
J. Lipid Res., May 1, 2002; 43(5): 732 - 741.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Tedgui and Z. Mallat
Anti-Inflammatory Mechanisms in the Vascular Wall
Circ. Res., May 11, 2001; 88(9): 877 - 887.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Xia, M. A. Vadas, K.-A. Rye, P. J. Barter, and J. R. Gamble
High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase Signaling Pathway. A POSSIBLE MECHANISM FOR PROTECTION AGAINST ATHEROSCLEROSIS BY HDL
J. Biol. Chem., November 12, 1999; 274(46): 33143 - 33147.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.